Raymond James Financial’s GeneDx Holdings WGS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-123,418
Closed -$8.47M – 5662
2026
Q2
$8.47M Sell
123,418
-486,655
-80% -$27.7M ﹤0.01% 2302
2026
Q1
$38.8M Buy
610,073
+104,732
+21% +$9.6M 0.01% 1017
2025
Q4
$65.5M Buy
505,341
+29,798
+6% +$4.09M 0.02% 686
2025
Q3
$51.2M Buy
475,543
+62,320
+15% +$6.79M 0.02% 794
2025
Q2
$38.1M Buy
413,223
+79,847
+24% +$6.27M 0.01% 931
2025
Q1
$29.5M Buy
333,376
+68,331
+26% +$5.93M 0.01% 1045
2024
Q4
$20.4M Buy
+265,045
New +$18.5M 0.01% 1303

Other funds holding WGS

Raymond James Financial's WGS Position: Q3 2026 in Review

Raymond James Financial sold out of GeneDx Holdings (WGS) in Q3 2026, closing a stake of 123,418 shares — an estimated $8.47M sold.

Raymond James Financial first reported a position in WGS in Q4 2024 and held it in 7 quarters. The position peaked at $65.5M in Q4 2025. 158 funds tracked by Wall St. Rank hold WGS as of Q3 2026.

  • Raymond James Financial reported no remaining GeneDx Holdings position as of Q3 2026 after selling out during the quarter.
  • Raymond James Financial sold 123,418 GeneDx Holdings shares in Q3 2026, an estimated $8.47M.
  • Raymond James Financial first reported a position in GeneDx Holdings in Q4 2024 and held it in 7 quarters.
  • Raymond James Financial's GeneDx Holdings position peaked at $65.5M in Q4 2025.
  • 158 funds tracked by Wall St. Rank held GeneDx Holdings as of Q3 2026.

Based on Raymond James Financial's 13F filing for Q3 2026, filed 12 Nov 2026.